Varenicline safer than warnings suggest: study

Safety warnings for varenicline should be reviewed because the quit-smoking drug does not increase the risk of cardiovascular or neuropsychiatric adverse effects any more than nicotine replacement therapy, researchers say.

A review by UK GPs of adverse events reported for smoking cessation therapies found varenicline was associated with a 20% reduced risk of ischaemic heart disease and a 34% lower risk of depression compared to users of nicotine replacement therapy (NRT).

Use of varenicline was also associated with a 44% lower risk of self-harm